The ProtecT trial: what can we expect?  by Roobol, Monique J & Bokhorst, Leonard P
Comment
1046 www.thelancet.com/oncology   Vol 15   September 2014
Profound changes in the detection of prostate cancer 
have occurred since prostate-speciﬁ c antigen (PSA) 
was introduced as a biomarker test for prostate 
cancer. Instead of the disease being detected at an 
advanced stage when symptoms caused by invasive 
growth emerged—with palliative treatment the main 
option—prostate cancer is diagnosed early on in the 
disease course. This early diagnosis, with the tumour 
still conﬁ ned to the prostate, means that many 
diﬀ erent, most often curative, treatment options 
can be considered. Indeed, results of the largest 
randomised screening trial showed that PSA testing, 
with its concomitant early treatment, substantially 
reduced the development of metastatic disease and 
prevented prostate cancer deaths.1,2 However, not only 
were potentially lethal tumours detected at an early, 
treatable stage, but also many non-lethal tumours were 
diagnosed.2 This over-diagnosis leads to substantial over-
treatment with its associated side-eﬀ ects.3 Therefore, 
whether treatment of early detected, localised cancers 
will result in a beneﬁ t or mainly cause harm is unclear. 
Furthermore, with many treatment options to choose 
from, evidence of one being most beneﬁ cial is needed.
Several researchers have attempted to compare the 
eﬀ ectiveness of diﬀ erent curative treatment options 
(including no or no initial radical treatment) for early, 
PSA-detected, localised prostate cancer. However, most 
failed because of diﬃ  culties in recruiting men willing to 
leave their cancer treatment to chance.4 In The Lancet 
Oncology, J Athene Lane and colleagues5 present the 
data for the recruitment phase of the Prostate testing 
for cancer and Treatment (ProtecT) trial. Because of a 
thoroughly designed study protocol, including the use 
of dedicated study nurses, the investigators succeeded 
in including the prespeciﬁ ed number of participants. 
1643 men were randomly assigned to either radical 
prostatectomy, radiation therapy, or active monitoring. 
Primary outcome analysis—comparison of prostate 
cancer mortality at a median of 10 years of follow-up—is 
anticipated for 2016. The group of investigators should 
already be commended for this careful work, which will 
result in a unique and highly informative dataset.
In addition to the primary analysis, an interesting topic 
will be the very detailed assessment of quality of life, 
which is measured at recruitment (before the diagnosis 
of prostate cancer), ﬁ rst biopsy, and during follow-up 
for at least 10 years. A detailed assessment of the eﬀ ect 
of diﬀ erent treatment modalities on quality of life might 
become crucial if the primary analysis shows a beneﬁ t in 
prostate cancer mortality for early active intervention. 
Other important data that will become available from 
ProtecT include the numbers of men switching from 
active monitoring to active treatment. Criteria to re-
assess treatment choice (a 50% PSA rise in 12 months—
ie, a PSA doubling time of less than 2 years) is quite 
restrictive. Active surveillance protocols advise men to 
switch to active treatment much sooner.6 Additionally, 
some men (and most likely their doctors) might switch 
to active treatment because of anxiety or other non-
protocol-based reasons (eg, high absolute PSA value).7 
However, the strict protocol and visits to a dedicated 
study nurse might reduce this number. 
The limitations of the design are clearly emphasised, 
being often a direct result of the inevitable, relatively 
long duration of the trial and the rapid evolvement in 
curative treatment modalities. A limitation that might 
aﬀ ect the ability of drawing deﬁ nite conclusions about 
the eﬀ ectiveness of the three conventional treatment 
options for localised prostate cancer is the expected 
prostate cancer mortality at 10 years of follow-up. The 
primary analysis consists of calculating the 10-year 
prostate cancer mortality risk and its conﬁ dence 
interval per treatment modality using adjusted Cox 
proportional hazard regression. Subsequently, an 
overall p value is calculated with the null hypothesis 
of equal risk across the three treatments. Pairwise 
signiﬁ cance tests (ie, comparing active monitoring 
with radical prostatectomy, active monitoring with 
radiation therapy, and radical prostatectomy with 
radiation therapy) are done only if the overall test yields 
a signiﬁ cant p value (<0·05). Initial estimates projected 
a 15% prostate cancer mortality in the active monitoring 
group at a median 10-year follow-up, which was later 
adjusted to a 10% prostate cancer mortality, based on 
more recent mortality data. With 10% prostate cancer 
mortality in the active monitoring group, sample size 
was calculated to be able to show a 4·6% absolute 
mortality diﬀ erence (the percentage point diﬀ erence), 
or hazard ratio of 0·54, compared with radical treatment 
with a power of 80%.
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But is this 10% prostate cancer mortality estimate, 
based on 2008 UK mortality statistics, realistic? As 
suggested by the investigators, opportunistic testing 
in the UK was and still is relatively rare, which implies 
that these UK mortality statistics are most likely not 
applicable to the PSA-based screen-detected cohort 
of ProtecT. This theory is supported by data from the 
Rotterdam section of the European Randomized Study 
of Screening for Prostate Cancer.8 Of all 1071 patients 
with PSA-based screen-detected prostate cancer at 
the initial screening visit (including advanced and 
metastatic disease), 78 (7·3%) died of prostate cancer 
after a median follow-up of 13 years. In the PIVOT 
trial at a median follow-up of 10 years, 31 (8·4%) 
of 367 prostate cancer deaths were reported in the 
observation group and 21 (5·8%) of 364 in the radical 
prostatectomy group (HR 0·63 [95% CI 0·36–1·09]).9 
As Lane and colleagues5 point out correctly, the ProtecT 
trial included men with much lower PSA values, lower 
age, and fewer high-stage cancers, and men in the 
active monitoring group were oﬀ ered radical treatment 
if progression occurred; all factors that will most likely 
decrease the expected prostate cancer mortality. In 
fact, the 10-year prostate cancer survival reported by 
active surveillance cohorts, with more similar tumour 
characteristics, ranges from 96–100%.10
Although a 4·6% absolute mortality diﬀ erence 
between active monitoring and radical treatment might 
be expected, the calculated 80% power will decrease 
substantially if fewer events occur than expected. 
After all, the precision of a study is proportional to the 
square of the number of events. Since the number of 
participants is ﬁ xed, the assumption about the number 
of events is crucial for the validity of the sample size 
calculation. Therefore, the continuation of gathering 
follow-up data is crucial. If, however, the expected 10% 
prostate cancer mortality in the active monitoring 
group turns out to be realistic, the causes of this 
discrepancy with the earlier mentioned observations will 
be interesting to explore. 
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 Future of ALK inhibition in non-small-cell lung cancer
Progress in deﬁ ning molecular targets of oncogenesis 
and drugs to inhibit cancer growth in speciﬁ c popula-
tions has led to augmented outcomes for patients and 
new expectations in the development of treatments. 
The EML4–ALK fusion protein was identiﬁ ed in patients 
with non-small-cell lung cancer (NSCLC) in 2007.1 
Rearrangements in the ALK gene lead to constitutive 
signalling, triggering transforming properties. Up to 
now, two drugs have been approved by the US Food 
and Drug Administration for ALK-rearranged NSCLC—
crizotinib and ceritinib.  
ALK inhibitors vary in potency against their target and 
in ability to overcome resistance; moreover, CNS activity 
diﬀ ers between agents. Crizotinib is an oral tyrosine 
kinase inhibitor that targets ALK, MET, and ROS1. It has 
an objective response of 61% and results in median 
progression-free survival of 9·7 months.2 Crizotinib 
was superior to chemotherapy as second-line treatment 
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